Our study focuses on GBM in comparison to low-grade astrocytoma and general glioma, that surpasses several diseases within the general group of glioma tumors, including both IDH-wildtype and IDH-mutant glioma. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).